Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples

Pharmacogenomics

Volumn 14, Issue 16, 2013, Pages 2005-2012

  Van Huis Tanja, Lieke ^a   Kweekel, Dinemarie ^a   Gelderblom, Hans ^a   Koopman, Miriam ^b   Punt, Kees ^c   Guchelaar, Henk Jan ^a   Van Der Straaten, Tahar ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

colorectal cancer; FFPE; GSTP1; loss of heterozygosity; pharmacogenomics; tumor

Indexed keywords

GENOMIC DNA; GLUTATHIONE TRANSFERASE P1;

ARTICLE; CANCER CHEMOTHERAPY; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DNA ISOLATION; DRUG CYTOTOXICITY; GENE FUNCTION; GENE IDENTIFICATION; GENOTYPE; GENOTYPING TECHNIQUE; GSTP1 GENE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MOLECULAR DYNAMICS; ONCOGENE; PYROSEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM;

COLORECTAL NEOPLASMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FORMALDEHYDE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LOSS OF HETEROZYGOSITY; METABOLIC DETOXICATION, DRUG; PARAFFIN EMBEDDING; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TISSUE FIXATION;

EID: 84889038658     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.169     Document Type: Article

References (38)

1. Swen JJ, Huizinga TW, Gelderblom H et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. 4(8), e209 (2007).
2. Swen JJ, Wilting I, de Goede AL et al. Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther. 83(5), 781-787 (2008).
3. Andrisin TE, Humma LM, Johnson JA. Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy 22(8), 954-960 (2002).
4. Casparie M, Tiebosch AT, Burger G et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell. Oncol. 29(1), 19-24 (2007).
5. Coura R, Prolla JC, Meurer L, Ashton-Prolla P. An alternative protocol for DNA extraction from formalin fixed and paraffin wax embedded tissue. J. Clin. Pathol. 58(8), 894-895 (2005).
6. Santos MC, Saito CP, Line SR. Extraction of genomic DNA from paraffin-embedded tissue sections of human fetuses fixed and stored in formalin for long periods. Pathol. Res. Pract. 204(9), 633-636 (2008).
7. Afzal S, Jensen SA, Vainer B et al. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann. Oncol. 20(10), 1660-1666 (2009).
8. Afzal S, Gusella M, Jensen SA et al. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. Pharmacogenomics 12(9), 1257-1267 (2011).
9. Braun MS, Richman SD, Thompson L et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J. Clin. Oncol. 27(33), 5519-5528 (2009).
10. Castillo-Fernandez O, Santibanez M, Bauza A et al. Methylenetetrahydrofolate reductase polymorphism (677 CT) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid. Arch. Med. Res. 41(6), 430-435 (2010).
11. Chua W, Goldstein D, Lee CK et al. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br. J. Cancer 101(6), 998-1004 (2009).
12. Etienne MC, Formento JL, Chazal M et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 14(12), 785-792 (2004).
13. Fernandez-Peralta AM, Daimiel L, Nejda N, Iglesias D, Medina Arana V, Gonzalez-Aguilera JJ. Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy. Int. J. Colorectal Dis. 25(2), 141-151 (2010).
14. Garcia-Aguilar J, Chen Z, Smith DD et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann. Surg. 254(3), 486-492 (2011).
15. Gordon MA, Gil J, Lu B et al. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics 7(1), 67-88 (2006).
16. Le Morvan V, Smith D, Laurand A et al. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 8(12), 1693-1703 (2007).
17. Nobili S, Napoli C, Landini I et al. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. Int. J. Cancer 128(8), 1935-1945 (2011).
18. Panczyk M, Balcerczak E, Piaskowski S, Jamroziak K, Pasz-Walczak G, Mirowski M. ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. Int. J. Colorectal Dis. 24(8), 895-905 (2009).
19. Suh KW, Kim JH, Kim do Y, Kim YB, Lee C, Choi S. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann. Surg. Oncol. 13(11), 1379-1385 (2006).
20. Pander J, Gelderblom H, Guchelaar HJ. Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs. Expert Opin. Pharmacother. 8(9), 1197-1210 (2007).
21. Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a Phase III randomised controlled trial. Lancet 370(9582), 135-142 (2007).
22. Salgado J, Zabalegui N, Gil C, Monreal I, Rodriguez J, Garcia-Foncillas J. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol. Rep. 17(2), 325-328 (2007).
23. Cecchin E, Agostini M, Pucciarelli S et al. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics J. 11(3), 214-226 (2011).
24. Cote JF, Kirzin S, Kramar A et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin. Cancer Res. 13(11), 3269-3275 (2007).
25. de Jong FA, Marsh S, Mathijssen RH et al. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res. 10(17), 5889-5894 (2004).
26. Zheng HT, Peng ZH, Li S, He L. Loss of heterozygosity analyzed by single nucleotide polymorphism array in cancer. World J. Gastroenterol. 11(43), 6740-6744 (2005).
27. Dang DT, Chen F, Kohli M, Rago C, Cummins JM, Dang LH. Glutathione S-transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res. 65(20), 9485-9494 (2005).
28. Ranganathan S, Tew KD. Immunohistochemical localization of glutathione S-transferases alpha, mu, and pi in normal tissue and carcinomas from human colon. Carcinogenesis 12(12), 2383-2387 (1991).
29. Adler V, Yin Z, Fuchs SY et al. Regulation of JNK signaling by GSTp. EMBO J. 18(5), 1321-1334 (1999).
30. Sidler D, Brockmann A, Mueller J et al. Thiazolide-induced apoptosis in colorectal cancer cells is mediated via the Jun kinase-Bim axis and reveals glutathione-S-transferase P1 as Achilles' heel. Oncogene 31(37), 4095-4106 (2012).
31. Adler V, Pincus MR. Effector peptides from glutathione-S-transferase-pi affect the activation of jun by jun-N-terminal kinase. Ann. Clin. Lab. Sci. 34(1), 35-46 (2004).
32. Marsh S, Mallon MA, Goodfellow P, McLeod HL. Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics 6(8), 873-877 (2005).
33. Balboa E, Duran G, Lamas MJ et al. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. Pharmacogenomics 11(6), 747-761 (2010).
34. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J. Natl Cancer Inst. 104(16), 1264-1268 (2012).
35. Pharoah PD, Abraham J, Caldas C. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J. Natl Cancer Inst. 104(16), 1263-1264 (2012).
36. Regan MM, Leyland-Jones B, Bouzyk M et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J. Natl Cancer Inst. 104(6), 441-451 (2012).
37. Stanton V. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J. Natl Cancer Inst. 104(16), 1265-1266 (2012).
38. Thiagalingam S, Laken S, Willson JK et al. Mechanisms underlying losses of heterozygosity in human colorectal cancers. Proc. Natl Acad. Sci. USA 98(5), 2698-2702 (2001).